Are Pangenotypic Treatments for Hepatitis C All the Same?
Last updated: July 2023
Over the years, treatment options for hepatitis C have improved significantly, including pangenotypic medications used to treat all genotypes (virus strains), including subtypes. Typically, pan-genotypic treatments have high cure rates, few side effects, and short treatment times (usually 8-12 weeks).
What is a pangenotypic hep C treatment?
Pangenotypic means a treatment that works on all genotypes (virus strains) of hepatitis C. The design of each pangenotypic treatment has certain chemical properties that will work on more than one genotype at the same time and have a high rate of efficiency targeting on specific liver conditions.
What is available?
There are currently three FDA approved pangenotypic treatments for hepatitis C in the United States.
Epclusa: Epclusa combines an NS5A inhibitor (sofosbuvir) and an NS5B inhibitor (velpatasvir). Epclusa is produced by Gilead Sciences.
Mavyret: Mayvret is a fixed-dose combination of glecaprevir, a hepatitis C virus (HCV) NS3/4A protease inhibitor, and pibrentasvir, an HCV NS5A inhibitor. Mavyret is produced by AbbVie.
Vosevi (sofosbuvir, velpatasvir, voxilaprevir). Vosevi is produced by Gilead Sciences.
What is the difference between treatments?
Your doctor will tell you which pangenotypic treatment or treatments could work for you based on your liver and medical conditions. Click the links below to learn more about side effects, indications, dosage information, and other important considerations for Epclusa, Mavyret, and Vosevi.